Li Zhou

This study identifies PABPC1 as a host factor that selectively targets viral RNA with short poly(A) tails, leading to degradation and antiviral defense, and develops a synthetic therapeutic based on this mechanism.

This paper develops a three-in-one mucosal vaccine, 3Rs-NC, that elicits broad neutralizing antibodies against three ACE2-using sarbecovirus clusters and provides durable protection in mice.

The paper constructs a mouse model expressing SARS-CoV-2 N protein to study infection with SARS-CoV-2 replicon delivery particles, showing peak viral load and lung injury at 4 days post-infection.